EpiBiologics, Inc.

SAN MATEO, CA · Founded 2021 · CIK 0001968158 · Biotech · Private

Bispecific antibodies that selectively degrade extracellular proteins

epibiologics.com →
Grants
—
No SBIR or STTR on record
Sector median: 1
Raised
$30M
1 Form D · Apr 2023
41 months since last filing
Contracts
—
No federal contracts on record
Patents
20
0 granted · 20 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Private capital raisedForm D · SEC$30,030,000
Form D · SEC

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2146Origin Life Sciences, Inc.—$2.9M
2147KALION, INC.—$6.7M
2148VIRONGY, LLC——
2149EpiBiologics, Inc.—$30M
2150Egalet Corp—$42M
2151Denali Medical II, Inc.—$4.0M
2152KANNALIFE SCIENCES, INC.—$1.5M

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 10 related persons
  • Samuel BjorkDirector
  • Alexandra CantleyDirector
  • Jason ColomaDirector
  • Rami HannoushDirector · Executive Officer
  • Michael KavanaughDirector
  • Ann Lee-KarlonDirector · Executive Officer
  • Craig LichtensteinExecutive Officer
  • Seiji MiyaharaDirector
  • Mitchell MutzDirector · Executive Officer
  • James WellsDirector

Patents

USPTO · 0 granted of 20
  • Binding Agents And Uses Thereofapplication
  • DEGRADATION OF cMET USING A BISPECIFIC BINDING AGENTapplication
  • Degradation Of Egfr Using A Bispecific Binding Agentapplication
  • Binding Agents And Uses Thereofapplication
  • Compositions And Methods Of Use For Binding Agentsapplication
  • Modified CH1 Heterodimeric Proteinsapplication
  • Binding Agents And Uses Thereofapplication
  • Binding Agents And Uses Thereofapplication
  • Compositions And Methods Of Use For Binding Agentsapplication
  • Degradation Of Cmet Using A Bispecific Binding Agentapplication
  • Bispecific Antibodies For Soluble, Intractable And Multiple Targets And Tissue Selectivityapplication
  • Degradation Of Egfr Using A Bispecific Binding Agentapplication

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.